H40.1
Conditions
Interventions
Group 1: Retrospective data collection of patients who underwent CyPass implantation between June 2009 and January 2013 and were routinely monitored for glaucoma diagnostics 3 and 6 months postoperati
Sponsors
Klinik für Augenheilkunde, Dietrich-Bonhoeffer-Klinikum,
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: - Patients with primary chronic open angle glaucoma - Implantation of the CyPass stent at the Department of Ophthalmology at the Dietrich-Bonhoeffer-Klinikum Neubrandenburg between March 2009 and September 2016 - data of follow-up visits available after 3 and 6 months - Patient age =18 years
Exclusion criteria
Exclusion criteria: - surgery canceled - more than 3 hours difference in the time of pre- and postoperative intraocular pressure measurement - Additional exclusion criterion for the evaluation of the data concerning the effectiveness: -- postoperative rTPA injection
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The main question is the retrospective data analysis to determinate the efficacy of supplemental intracameral bevacizumab (= Avastin) injection after CyPass microstent implantation (2009-2016) on the intraocular pressure and the postoperative number of hypotensive local drugs. | — |
Secondary
| Measure | Time frame |
|---|---|
| The auxiliary question is te retrospective analysis to determine the safety of the additional injection of Bevacizumab (=Avastin) into the anterior chamber based on slit-lamp microscopic findings compared to CyPass implantation without Avastin postoperative (2009-2016). | — |
Countries
Germany
Contacts
Public ContactUlrike Holland
Klinik für Augenheilkunde, Dietrich-Bonhoeffer-Klinikum
Outcome results
None listed